The Valley Desk

ArticleAntioxidants (Basel, Switzerland)Published

CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Temple University. Affiliation source

Publication record

Type
Article
Venue
Antioxidants (Basel, Switzerland)
Published
Subject terms
Oxidative stress; NRF2; Nafld; Fatty Liver Disease; Crispr/cas9; Hmox1
PubMed ID
37507903
PubMed Central ID
PMC10375998
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal